Abbott | ABT - Cash And Equivalent


Abbott reported $6.8B in Cash and Equivalent for its fiscal quarter ending in March of 2026.





Cash And Equivalent Change Date
Abbott USD 6.8B 1.72B Mar/2026
Agilent USD 1.76B 49M Jun/2026
AtriCure USD 167.79M 21.62M Jun/2026
Baxter International USD 2.15B 133M Jun/2026
Becton, Dickinson and Co. USD 708M 105M Jun/2026
Bio-Rad Laboratories USD 517M 9.8M Jun/2026
Boston Scientific USD 539M 914M Jun/2026
Cooper Companies USD 138.8M 13.9M Mar/2026
Danaher USD 4.35B 1.35B Jun/2026
Dexcom USD 1.1B 13.2M Jun/2026
Edwards Lifesciences USD 2.9B 500M Jun/2026
Globus Medical USD 507.74M 53.2M Jun/2026
Insulet USD 534.9M 54.5M Jun/2026
Integra LifeSciences USD 214.42M 22.39M Jun/2026
Intuitive Surgical USD 8.63B 646.3M Jun/2026
J&J USD 20.42B 1.27B Jun/2026
Medtronic USD 1.69B 258M Jun/2026
Merit Medical Systems USD 448.7M 39.38M Jun/2026
Pfizer USD 976M 727M Jun/2026
Solventum Corp USD 403M 158M Jun/2026
Stryker USD 3.39B 513M Jun/2026
Tandem Diabetes Care USD 62.82M 116.51M Jun/2026
Teleflex USD 300.16M 9.25M Jun/2026
Terumo JPY 280.49B 63.34B Mar/2026
Thermo Fisher Scientific USD 3.25B 6.6B Mar/2026
Zimmer Biomet Holdings USD 410M 14.2M Jun/2026